The leading 3D-printing company in Israel, Nano Dimension, is getting closer to creating a new 3D bioprinter that utilizes stem cells. Following successful experiments recently conducted in the lab experiments, the new technology will pave a way for bioprinting human organs.

According to Digital Trends, Nano Dimensions teamed up with Accellta, an Israeli research company specializing in stem cells to develop its research. The two companies combined their work, namely Nano Dimension's high speed and innovative 3D printing electronics and Accellta's high-quality stem cell suspension technologies. With the tests, the biotech firm could create a large number of high-qualityy cells faster with the potential 3D bioprinter.

Amit Dror, CEO of Nano Dimension said their efforts in the project will be of great use to medical research. "3D printing of living cells is a technology that is already playing a significant role in medical research," Dror explained. He also added, " In order for it to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control, and viability as well as cell availability and bio-ink technologies."

Market research company, Grand View Research, predicted the market for bioprinting will quickly increase over the next decade to as much as $6 billion in 2024 from $481 million in 2014, Geek Time reported. In this kind of industry, numerous rival firms are also competing, including EnvisionTEC's 3D Bioplotter, Organovo's NovoGen MMX 3D BioPrinter, RegenHU, Cyfuse Biomedical and among others.

The Ness Ziona-based firm, which mainly focuses on printing-based nanotechnology took a significant transition to biotechnology and electronics.  Following the research, Nano Dimension and Accellta predict that advancement in the study could help improve drug tests, biotprinting tissue and cosmetic tests.